Translate page

iCMLf Conversations on CML - Recordings available to view

The iCMLf is hosting regular 'iCMLf Conversations on CML' with renowed experts in CML that address key topics in CML management. You can view recordings of the conversations here. The content of the presentations express the individual opinions of the respective experts.

Keynote presentations from the recipients of the 2019 iCMLf Prizes

At the 21th Annual John Goldman Conference on CML in Bordeaux the iCMLf Directors awarded the Foundation’s 2019 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the Rowley Prize and the iCMLf Prize keynote presentations here. Unfortunately François-Xavier Mahon's presentation on 'Curing CML: To be, or not to be, that is the question' (Goldman Prize) is not available as a web stream.

Collage 2019 iCMLf Prizes


  • 2019 Rowley Prize: Professor Michael Deininger
  • 2019 Goldman Prize: Professor François-Xavier Mahon
  • 2019 iCMLf Prize: Dr Carolina Pavlovsky



Perspectives on the scientific aspects of the meeting from Professor Daniela Krause
Georg-Speyer Haus
University of Frankfurt (Germany) 

  • Concept of treatment-free remission
    • Immunological surveillance after treatment discontinuation
    • Analysis of different immune subsets 
    • A mathematical model for prediction of good response
  • Results from the workshop on metabolism 
  • The role of inflammation in CML
  • Aging - mutations that occur with aging
  • Therapy resistance
  • Stem cells and microenvironment
  • Existence of BCR-ABL independent mutations
  • Immunotherapy - resistance to CAR-T cells

 We apologize for the background noise in this video.

{rscomments off}

Highlights from the John Goldman Conference on CML 2019:
CML experts give their personal perspectives

Perspectives on the clinical aspects of the meeting from Professor Jorge Cortes
Georgia Cancer Center
Augusta University, Augusta (USA)

  • Treatment-free remission as a new goal for patients with CML
    • Long-term follow-up data from the STIM study
    • Treatment strategies for patients with early and late relapse 
    • Biomarkers to predict a higher probability of relapse
    • Pharmacoeconomics of treatment discontinuation
  • Complex genetics of CML - the work of the Genomics Alliance
  • Clinical trial updates
    • SPIRIT trial
    • BEYOND study
    • Asciminib combinations
  • Fatigue during TKI therapy

 {rscomments off}

Highlights from the John Goldman Conference on CML 2018:
CML experts give their personal perspectives

In Spanish:
Perspectivas sobre los estudios de discontinuación de terapia que se mostraron
Dr Carolina Pavlovsky
FUNDALEU - Fundación para combatir la leucemia
Buenos Aires - Argentina

  • Resumen de los estudios de discontinuacíon de terapia más importantes, que incluyen
    • ENESTFreedom
    • ENESTStop
    • DASFree
  • Análisis de los estudios actuales sobre biomarcadores y otros factores predictivos que pueden predecir el éxito terapéutico y que pueden mostrar qué mutaciones pueden ser relevantes en pacientes resistentes

Highlights from ASH 2018 Annual Meeting:

At ASH in San Diego, the CML education session was entitled 'With Great Success Comes Great Responsibility'. Professors Jane Apperley, Timothy Hughes and Charles Craddock gave respective presentations on the treatment of CML with TKIs, molecular monitoring to aid clinical decision making and the role of transplantation in managing CML. Below are interviews from the presenters on their perspectives on the session. 

These summaries are brought to you with support from Bristol Myers Squibb.

In addition, we are pleased to be able to offer you a complete scientific summary of the education session on CML. This also contains a summary of relevant abstracts on; TFR failure, resistance and new drug development.

Download the scientific summary report here

Summaries of the ASH CML Education Session

The Argument for Using Imatinib in CML

Professor Jane Apperley
Imperial College London, London, UK

Jane Apperley described the outcome of newly diagnosed patients newly treated with first or second generation TKIs. She discussed balancing the desire to achieve the deep molecular responses that permit trials of TKI discontinuation with the potential adverse effects of earlier use of the more potent TKI's, and provided pragmatic advice regarding treatment decisions.